AOC1 and inflammatory bowel disease: Clinical evidence supports PG’s efficacy: 15.2% reduction in fasting blood glucose levels in T2DM, 28.5% decrease in diamine oxidase (DAO) activity in IBD, and improvements in cognitive function scores (Mini-Mental State Examination scores increased by 2.4 points) in mild cognitive impairment.